label these functions
Reading File
This is a diagram of an IgG antibody (immunoglobulin). Here are the labeled regions and their functions:
| Label | Structure | Function |
|---|---|---|
| A | Fab region (Fragment antigen-binding) of the light chain | Contains the variable (V) domain of the light chain; contributes to antigen binding |
| B | Fab region of the heavy chain (variable + constant domains) | Contains the variable (V) domain of the heavy chain; together with A, forms the antigen-binding site |
| C | Fab arm (right side) | Mirror of the left Fab arm — binds a second copy of the same antigen (provides bivalency) |
| D | Hinge region | Flexible disulfide-bond region connecting the Fab arms to the Fc; allows conformational flexibility during antigen binding |
| E | Fab region (right light chain variable domain) | Antigen-binding variable domain on the right arm |
| F | Fc region (Fragment crystallizable) | Mediates effector functions: complement activation (C1q binding), binding to Fc receptors on immune cells (NK cells, macrophages, neutrophils), neonatal Fc receptor (FcRn) binding for IgG half-life extension |
Key concept: The "V" domains visible in labels A, B, C, and E represent the variable regions, which together form the complementarity-determining regions (CDRs) — the hypervariable loops that directly contact antigen. The blue shading represents the heavy chain; red shading represents the light chain.
Name and describe the main genetic aberrations both molecular and chromosomal that are associated with blood malignancies
Reading File
Finding Sources
Finding Sources
Searching PubMed
"hematologic malignancies" AND "chromosomal aberrations" AND "molecular mutations"
Finding Sources
Finding Sources
Searching PubMed
"hematologic malignancies" AND "genetic aberrations"
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Excellent. I now have comprehensive textbook data from Robbins Pathology, Henry's Clinical Laboratory Methods, Harrison's, and Goldman-Cecil Medicine. Here is a thorough synthesis:
Genetic Aberrations in Blood Malignancies
Blood malignancies (leukemias, lymphomas, myeloma, myelodysplastic/myeloproliferative neoplasms) are defined by two broad categories of genetic lesion: chromosomal aberrations (visible or detectable at the cytogenetic level) and molecular mutations (point mutations, small insertions/deletions detectable by sequencing).
I. Chromosomal Aberrations
A. Translocations — Fusion Genes
These create chimeric proteins with constitutive oncogenic activity.
| Translocation | Disease | Genes Fused | Mechanism |
|---|---|---|---|
| t(9;22)(q34;q11) — Philadelphia chromosome | CML (95%), B-ALL (25%) | BCR::ABL1 | Creates a constitutively active non-receptor tyrosine kinase → uncontrolled proliferation, blocked apoptosis. Targeted by imatinib/TKIs. |
| t(8;21)(q22;q22) | AML (M2) | RUNX1T1::RUNX1 | Disrupts the core-binding factor (CBF) transcription complex → blocks myeloid differentiation. Favorable prognosis. |
| t(15;17)(q22;q21) | Acute promyelocytic leukemia (APL/AML-M3) | PML::RARA | Fusion protein blocks maturation at promyelocyte stage; all-trans retinoic acid (ATRA) and arsenic trioxide cause degradation of the fusion, restoring differentiation. |
| inv(16)(p13;q22) / t(16;16) | AML (M4Eo) | CBFB::MYH11 | Also disrupts CBF complex; favorable prognosis. |
| t(8;14)(q24;q32) | Burkitt lymphoma | MYC::IGH | Juxtaposing MYC to the highly active Ig heavy-chain enhancer → massive MYC overexpression → unrestrained proliferation. Less commonly t(2;8) or t(8;22). |
| t(14;18)(q32;q21) | Follicular lymphoma (~90%) | IGH::BCL2 | BCL2 overexpression → failure of programmed cell death → accumulation of B-cells. |
| t(11;14)(q13;q32) | Mantle cell lymphoma | CCND1::IGH | Cyclin D1 overexpression → G1/S cell cycle progression bypass. |
| t(11;18), t(1;14), t(14;18) | MALT lymphoma | API2::MALT1 / BCL10::IGH | NF-κB activation → anti-apoptotic signaling; associated with H. pylori and other chronic antigen stimulation. |
| t(2;5)(p23;q35) | Anaplastic large cell lymphoma (ALCL) | NPM1::ALK | Creates constitutively active ALK tyrosine kinase → JAK-STAT, RAS, PI3K signaling. Targeted by ALK inhibitors (crizotinib). |
| t(4;14), t(14;16), t(11;14) | Multiple myeloma | FGFR3/MMSET, MAF, CCND1 | IgH translocations dysregulate multiple oncogenes; adverse prognosis markers in myeloma. |
B. Translocations — Enhancer Substitution (Overexpression)
- Burkitt lymphoma t(8;14): MYC is not mutated but placed under constitutive Ig enhancer control, driving relentless transcription of the MYC proto-oncogene. The same principle applies in follicular lymphoma (BCL2) and mantle cell lymphoma (CCND1).
C. Deletions / Monosomies
| Lesion | Disease | Effect |
|---|---|---|
| del(5q) | MDS | Loss of RPS14 → haploinsufficiency, erythroid failure. Lenalidomide is specifically active in del(5q) MDS. |
| del(7q) / -7 | AML, MDS | Loss of tumor suppressor genes; adverse prognosis, associated with therapy-related neoplasms. |
| del(13q14) | CLL, myeloma | Loss of miR-15a/16-1 → BCL2 overexpression (most common CLL aberration; favorable if isolated). |
| del(17p) / -17p | CLL, myeloma, MDS | Loss of TP53 → resistance to chemotherapy; very poor prognosis. |
| del(11q22-23) | CLL | Loss of ATM; intermediate prognosis. |
| del(20q) | MDS, MPN | Loss of tumor suppressor genes; characteristic of MDS/MPN. |
D. Trisomies / Gains
| Lesion | Disease | Notes |
|---|---|---|
| +12 (trisomy 12) | CLL | Intermediate prognosis; often with NOTCH1 mutations. |
| Hyperdiploidy (>50 chromosomes) | B-ALL (pediatric) | Gains of chromosomes 4, 10, 17; favorable prognosis. |
| +8 | AML, MDS | Common secondary change; unfavorable in MDS. |
| +9 | CML | Residual after t(9;22); prognostic significance under study. |
E. Inversions
| Lesion | Disease | Effect |
|---|---|---|
| inv(16)(p13q22) | AML | CBFB::MYH11 fusion (see above) |
| inv(3)(q21;q26) / t(3;3) | AML, MDS | EVI1 overexpression; very adverse prognosis. |
II. Molecular Mutations
A. Tyrosine Kinase / Signaling Pathway Mutations
| Gene | Disease | Mutation | Effect |
|---|---|---|---|
| FLT3-ITD | AML (~25–30%) | Internal tandem duplication in juxtamembrane domain | Constitutive FLT3 activation → proliferation, survival; worst prognosis in AML; targeted by midostaurin, quizartinib. |
| FLT3-TKD | AML (~7%) | Point mutation D835 in tyrosine kinase domain | Similar but weaker than ITD; less clearly adverse. |
| KIT (D816V) | AML with t(8;21) or inv(16), mastocytosis | Gain-of-function missense | Activates stem cell factor receptor; reverses the favorable prognosis of CBF-AML; targeted by avapritinib. |
| JAK2 V617F | MPN: PV (~95%), ET (~55%), MF (~50%) | Val→Phe substitution in pseudokinase domain | Constitutive JAK-STAT signaling → erythroid/megakaryocyte/myeloid expansion. Targeted by ruxolitinib. |
| CALR (exon 9 ins/del) | ET (~25%), MF (~25%) | Frameshift → abnormal C-terminus binds and activates MPL | Activates JAK-STAT independently of JAK2; type 1 mutations have better prognosis than type 2. |
| MPL W515L/K | ET, MF (~5%) | Gain-of-function in thrombopoietin receptor | JAK-STAT activation. |
| RAS (NRAS/KRAS) | AML (~10–20%), JMML, MDS | Point mutations at codons 12, 13, 61 | GTPase-deficient RAS locked in GTP-bound active state → continuous MAPK/PI3K signaling. |
| BRAF V600E | Hairy cell leukemia (~100%) | Valine→glutamate substitution | Constitutive MAPK activation; highly specific marker; targeted by vemurafenib. |
B. Transcription Factor Mutations
| Gene | Disease | Effect |
|---|---|---|
| NPM1 | AML (~25–35%) | Frameshift mutation → cytoplasmic mislocalisation of nucleophosmin |
| CEBPA | AML (~10%) | Biallelic mutations (N-terminal + bZIP domain) |
| RUNX1 (AML1) | AML, MDS, ALL | Point mutations or deletions |
| IKZF1 (Ikaros) | ALL (especially Ph+ B-ALL) | Deletions, dominant-negative isoforms |
| PAX5 | B-ALL | Deletions/mutations |
C. Epigenetic Modifier Mutations
| Gene | Disease | Effect |
|---|---|---|
| DNMT3A (R882H/C) | AML (~20–30%), CHIP | DNA methyltransferase — loss of function → hypomethylation at specific loci; poor prognosis; co-occurs with NPM1, FLT3-ITD. |
| TET2 | AML, MDS, MPN, CHIP (~20%) | Loss of function → impaired conversion of 5-methylcytosine to 5-hydroxymethylcytosine → aberrant methylation. |
| IDH1 (R132) / IDH2 (R140, R172) | AML (~20%), MDS, MPN | Neomorphic gain-of-function → produces 2-hydroxyglutarate (oncometabolite) → inhibits TET2, histone demethylases → DNA/histone hypermethylation → differentiation block. Targeted by ivosidenib (IDH1) and enasidenib (IDH2). |
| EZH2 | MDS, MPN, DLBCL, follicular lymphoma | Loss-of-function (myeloid) or gain-of-function (lymphoid) |
| ASXL1 | MDS, MF (~40–50%), CMML | Truncating mutations |
D. Spliceosome Mutations
Mutations in RNA splicing factors are almost uniquely enriched in myeloid neoplasms and are essentially mutually exclusive with each other.
| Gene | Disease | Effect |
|---|---|---|
| SF3B1 (K700E) | MDS-ring sideroblasts (~80%), CLL | Aberrant 3′ splice site selection → abnormal mRNA processing; SF3B1 mutation defines MDS-RS in the WHO classification. |
| SRSF2 (P95) | MDS, CMML, MF | Aberrant exon inclusion/skipping. |
| U2AF1 (S34, Q157) | MDS | Altered U2 snRNP auxiliary factor. |
| ZRSR2 | MDS | X-linked; affects minor intron splicing. |
E. Tumor Suppressor Mutations
| Gene | Disease | Effect |
|---|---|---|
| TP53 | AML (~8–10%; high in therapy-related/complex karyotype), MDS, CLL, myeloma | Loss of p53-mediated apoptosis and cell cycle arrest; biallelic loss has the worst prognosis across all blood cancers; predictive of resistance to alkylators and hypomethylating agents. |
| ATM | CLL, MCL | DNA damage checkpoint loss; del(11q) removes one allele; somatic mutation removes the second. |
| RB1 | Myeloma, ALL | Retinoblastoma protein loss → cell cycle dysregulation. |
F. Cohesin Complex Mutations
| Gene | Disease | Effect |
|---|---|---|
| STAG2, RAD21, SMC1A, SMC3 | AML, MDS | Cohesin holds sister chromatids together; mutations disrupt chromatin organisation and gene regulation; adverse prognosis in AML. |
G. Tumor-Specific Molecular Markers
| Marker | Disease | Clinical Relevance |
|---|---|---|
| BCR::ABL1 p210 | CML | Diagnostic; quantitative PCR monitors minimal residual disease (MRD) and TKI response. |
| BCR::ABL1 p190 | B-ALL | More aggressive; same TKI therapies. |
| PML::RARA | APL | Diagnostic; ATRA + arsenic trioxide curative in most cases; PCR monitors remission. |
| JAK2 V617F | MPN | Diagnostic clonal marker; ruxolitinib target. |
| NOTCH1 / FBXW7 | T-ALL, CLL | NOTCH1 gain-of-function drives T-ALL (~50%); NOTCH1/FBXW7 mutations in CLL may be adverse but respond to venetoclax. |
| MYD88 L265P | Waldenström macroglobulinemia (~90%), activated B-cell DLBCL | TLR-pathway constitutive activation → NF-κB; ibrutinib sensitive. |
| CARD11, CD79B, MYD88 | ABC-subtype DLBCL | NF-κB "chronic active BCR signaling" pathway; targeted by ibrutinib. |
| BTK / PLCG2 | CLL (acquired under ibrutinib) | Resistance mutations; switch to venetoclax or pirtobrutinib. |
Key Conceptual Points
-
Two-hit model: Most blood cancers require cooperation of at least two classes of mutation — one that blocks differentiation (e.g., PML::RARA, RUNX1 mutations) and one that drives proliferation/survival (e.g., FLT3-ITD, RAS). This is the Gilliland "two-hit" hypothesis for AML.
-
Clonal hematopoiesis of indeterminate potential (CHIP): Mutations in DNMT3A, TET2, ASXL1, and TP53 can precede overt malignancy by years, representing pre-malignant clonal expansion.
-
Mutual exclusivity and co-occurrence: IDH1/IDH2 and TET2 are mutually exclusive (same pathway); FLT3-ITD and NPM1 co-occur frequently; NPM1 and biallelic CEBPA mutations characteristically appear with normal karyotype.
-
Prognostic stratification: The 2022 ELN and ICC/WHO 5th edition classifications integrate cytogenetics and molecular mutations into risk groups that directly guide therapy (e.g., transplant vs. chemotherapy alone vs. targeted agents).
Sources: Robbins & Cotran Pathologic Basis of Disease (10th ed.); Henry's Clinical Diagnosis and Management by Laboratory Methods; Harrison's Principles of Internal Medicine 22E (2025); Goldman-Cecil Medicine; Goodman & Gilman's Pharmacological Basis of Therapeutics.
This is a shared conversation. Sign in to Orris to start your own chat.